Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors

Autor:	M. Macy, T. Cash, N. Pinto, J.G. Pressey, L. Szalontay, W.L. Furman, A. Bukowinski, J.H. Foster, G.K. Friedman, J. HaDuong, E. Fox, B.J. Weigel, J. Grevel, F. Huang, C. Phelps, B.H. Childs, J. Chung, S. Chaturvedi, A. Schulz, S.G. DuBois
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	European Journal of Cancer. 174:S28-S29
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(22)00878-4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3b67b0c8ede7e4099a21a6d231816389 https://doi.org/10.1016/s0959-8049(22)00878-4 Zobrazit plný text záznamu Full Text from ScienceDirect